Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.55 USD 0.65%
Market Cap: 188m USD

Relative Value

IKT doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of IKT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IKT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
21
Median 3Y
591.2
Median 5Y
596.7
Industry
7.9
vs History
vs Industry
Median 3Y
-10
Median 5Y
-19.1
Industry
23.7
Forward
-2.9
vs History
vs Industry
Median 3Y
-14
Median 5Y
-20.6
Industry
22
vs History
vs Industry
Median 3Y
-13.7
Median 5Y
-20.5
Industry
23.8
vs History
87
vs Industry
50
Median 3Y
12.3
Median 5Y
21.3
Industry
3.3
vs History
vs Industry
52
Median 3Y
540.3
Median 5Y
578.2
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
30
Median 3Y
-8.3
Median 5Y
-18.2
Industry
6.4
vs History
vs Industry
28
Median 3Y
-8.3
Median 5Y
-18.1
Industry
7
Forward
-2.1
vs History
vs Industry
32
Median 3Y
-9.6
Median 5Y
-19.5
Industry
8.3
vs History
vs Industry
28
Median 3Y
-9.6
Median 5Y
-19.3
Industry
6.5
vs History
69
vs Industry
7
Median 3Y
297.6
Median 5Y
449.2
Industry
5.7

Multiples Across Competitors

IKT Competitors Multiples
Inhibikase Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
188m USD 0 -3.9 -2.2 -2.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
400.4B USD 6.7 170.6 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
173.6B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
151.3B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115B USD 9.8 31.3 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD 5.6 17.4 16.5 18.8
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.4 1 213.7 158 191.6
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.1 33.1 57.8 59.4
P/S Multiple
Revenue Growth P/S to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average P/S: 3 381 205.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 809 907.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 083.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average P/E: 191.1
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 213.7
N/A N/A
NL
argenx SE
XBRU:ARGX
33.1
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBITDA: 39.4
Negative Multiple: -2.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
NL
argenx SE
XBRU:ARGX
57.8
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBIT: 45.5
Negative Multiple: -2.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A
NL
argenx SE
XBRU:ARGX
59.4
N/A N/A